Informations générales (source: ClinicalTrials.gov)
Economic Evaluation of Innovative Molecular Analyses in Onco-haematology (PRME-K 2016)
Observational
Assistance Publique - Hôpitaux de Paris (Voir sur ClinicalTrials)
octobre 2018
octobre 2020
29 juin 2024
To evaluate the impact of innovative molecular diagnostics on the clinical management of
patients with haematological malignancies via updated Appropriate-Prescribing-Guides
including Next-Generation Sequencing (NGS) panels, facilitated therapeutic orientation,
and optimised use of costly novel therapeutics and risk-adapted treatment. A
micro-costing approach will be used to develop flat fee tarifs for NGS analyses.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| AP-HP - Hôpital Necker-Enfants Malades | Professor Elizabeth Macintyre | Contact (sur clinicalTrials) | |||
| AP-HP - Hôpital Saint Antoine | Professor François Delhommeau | Contact (sur clinicalTrials) | |||
| CLCC INSTITUT GUSTAVE ROUSSY | Dr Christophe Marzac | Contact (sur clinicalTrials) | |||
| IFSI AVICENNE (AP-HP) | Professor Fanny Baran-Marszak | Contact (sur clinicalTrials) | |||
| IFSI COCHIN-LA ROCHEFOUCAULT (AP-HP) | Professor Olivier Kosmider | Contact (sur clinicalTrials) | |||
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre Henri-Becquerel - Rouen - France | Dr Martine Becker | Contact (sur clinicalTrials) | |||
| Centre hospitalier universitaire de Saint-Étienne - Saint-Étienne - France | Dr Pascale Flandrin Gresta | Contact (sur clinicalTrials) | |||
| CHRU Brest - Brest - France | Dr Eric Lippert | Contact (sur clinicalTrials) | |||
| CHU Angers - Angers - France | Dr Odile Blanchet | Contact (sur clinicalTrials) | |||
| CHU Estaing - Clermont Ferrand - France | Professor Marc Berger | Contact (sur clinicalTrials) | |||
| CHU Hôtel Dieu - Nantes - France | Dr Yannick LE BRIS | Contact (sur clinicalTrials) | |||
| CHU Limoges - Limoges - France | Dr David Rizzo | Contact (sur clinicalTrials) | |||
| CHU Lyon Sud Pierre Bénite - Lyon - France | Dr Pierre Sujobert | Contact (sur clinicalTrials) | |||
| CHU Montpellier - Montpellier - France | Dr Melissa Alamé | Contact (sur clinicalTrials) | |||
| CHU Robert Debré Reims - Reims - France | Dr Pascale Cornillet-Lefebvre | Contact (sur clinicalTrials) | |||
| CHU Toulouse - Toulouse - France | Professor Eric Delabesse | Contact (sur clinicalTrials) | |||
| Hôpital Robert Debré - 75004 - Paris - France | Professor Hélène Cave | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre hospitalier régional universitaire de Lille - 59000 - Lille - Hauts De France - France | Professor Claude PREUDHOMME | Contact (sur clinicalTrials) | |||
| CHRU Dijon Bourgogne - Dijon - France | Professor Mary Callanan | Contact (sur clinicalTrials) | |||
| CHU de Bordeaux - Bordeaux - France | Dr Audrey Bidet | Contact (sur clinicalTrials) | |||
| CHU Nice - Nice - France | Professor Sophie Raynaud | Contact (sur clinicalTrials) | |||
| CHU Pontchaillou - Rennes - France | Professor Thierry Fest | Contact (sur clinicalTrials) | |||
| Hôpital Henri Mondor AP-HP - Créteil - France | Dr Dominique Bories | Contact (sur clinicalTrials) | |||
| Hôpital Pitié-Salpêtrière AP-HP - 75004 - Paris - France | Professor Frédéric Davi | Contact (sur clinicalTrials) | |||
| Hôpital St Louis AP-HP - 75004 - Paris - France | Dr Jean-Michel Cayuela | Contact (sur clinicalTrials) | |||
| Hôpitaux Universitaires Strasbourg - Strasbourg - France | Dr Laurent Miguet | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Patients with haematological malignancies referred for molecular diagnosis workup.
RuBIH2 will focus on 5 clinical situations in onco-haematology:
1. Myelodysplasia (MDS)
2. Acute lymphocytic leukemia (T) (ALL)
3. Lymphoproliferative disorders (LPD)
4. Acute myeloblastic leukemia (AML)
5. Myeloproliferative disorders (MPD)
- Patients with haematological malignancies referred for molecular diagnosis workup.
RuBIH2 will focus on 5 clinical situations in onco-haematology:
1. Myelodysplasia (MDS)
2. Acute lymphocytic leukemia (T) (ALL)
3. Lymphoproliferative disorders (LPD)
4. Acute myeloblastic leukemia (AML)
5. Myeloproliferative disorders (MPD)
- Other haematological diseases not included in the list above.